#1701797 Waist-to-height ratio shifts over time in tirzepatide-treated participants – post hoc analysis in SURMOUNT-1 and SURMOUNT-2

Waist-to-height ratio (WHtR) is a practical estimate of central adiposity and can be a better predictor of cardiometabolic disease than body mass index (BMI). Tirzepatide (TZP) is a once weekly GIP/GLP-1 receptor agonist approved in the US for treatment of type 2 diabetes and obesity. The objectives of this post hoc analyses of SURMOUNT-1 (SM-1) and SURMOUNT-2 (SM-2) were to assess change from baseline (BL) to Week 72 in WHtR and to assess shift from BL to Week 72 in WHtR risk categories as defined by recent NICE guidelines for individuals with BMI < 35 kg/m2: "healthy" (WHtR ≤0.49), "increased" (WHtR >0.49 to ≤0.59), and "high" (WHtR >0.59).